OverviewSuggest Edit

89Bio is a clinical-stage biopharmaceutical company. The company mainly addresses urgent needs in the liver and metabolic disorders by the development of the treatment of non-alcoholic steatohepatitis.

TypePublic
Founded2018
HQSan Francisco, CA, US
Website89bio.com

Latest Updates

Employees (est.) (Dec 2019)19(+12%)
Job Openings5
Share Price (Oct 2021)$17.5
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at 89bio

Rohan Palekar

Rohan Palekar

CEO, Director
Hank Mansbach

Hank Mansbach

Chief Medical Officer
Ryan Martins

Ryan Martins

Chief Financial Officer
Quoc Le-Nguyen

Quoc Le-Nguyen

Chief Technical Operations Officer and Head of Quality
Steven Altschuler

Steven Altschuler

Chairman
Michael Baldwin

Michael Baldwin

VP, Quality Assurance
Show more

89bio Office Locations

89bio has offices in San Francisco and Herzliya
San Francisco, CA, US (HQ)
142 Sansome St 2nd floor, San Francisco
Herzliya, IL
6 Hamada Street 4673340, Israel
Show all (2)

89bio Financials and Metrics

89bio Revenue

USD

Net income (FY, 2020)

(49.5m)

EBIT (FY, 2020)

(49.4m)

Market capitalization (21-Oct-2021)

351.1m

Closing stock price (21-Oct-2021)

17.5

Cash (31-Dec-2020)

98.2m
89bio's current market capitalization is $351.1 m.
USDFY, 2018FY, 2020

General and administrative expense

1.5m13.2m

R&D expense

13.7m36.2m

Operating expense total

15.2m49.4m

EBIT

(15.2m)(49.4m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

11.2m93.3m98.2m

Prepaid Expenses

2.0m5.5m

Current Assets

11.3m95.3m210.2m

PP&E

33.0k155.0k166.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

21.9m16.2m85.5m68.2m

Prepaid Expenses

362.0k1.9m1.4m

Current Assets

22.3m16.6m87.4m75.3m

PP&E

46.0k49.0k204.0k191.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(16.2m)(57.4m)(49.5m)

Depreciation and Amortization

6.0k17.0k60.0k

Accounts Payable

1.5m(520.0k)1.1m

Cash From Operating Activities

(12.5m)(25.5m)(46.2m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(7.4m)(19.4m)(38.1m)(10.5m)(22.3m)

Depreciation and Amortization

7.0k12.0k12.0k29.0k

Accounts Payable

208.0k(541.0k)1.6m3.1m2.1m

Cash From Operating Activities

(6.6m)(8.1m)(14.3m)(7.8m)(19.3m)
Show all financial metrics

89bio Operating Metrics

Oct, 2019

Drugs in Development

1

Patents Issued

2

Phase I Trials Products

1

Phase I/II Trials Products

1
Show all operating metrics

89bio Acquisitions / Subsidiaries

Company NameDateDeal Size
89Bio Ltd.
89bio Management, Inc.
UAB 89bio Lithuania

89bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

89bio Online and Social Media Presence

Embed Graph

89bio News and Updates

89bio to Participate in the Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will…

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100’s potential benefits on histology endpoints - - Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100’s potential benefits on …

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will …

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH

SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of ENLIVEN, a Ph…

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

- Received written guidance from FDA related to trial design and agreement to use liquid formulation -- ENLIVEN trial to initiate as planned in 2Q21 -

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH
Show more

89bio Blogs

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update Content Import Thu, 08/12/2021 - 16:05 89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update 08/12/2021 This release is a backfill from a News Wire …

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update Content Import Wed, 05/12/2021 - 16:06 89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update 05/12/2021 This release is a backfill from a News Wire …

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21 - SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc.

89bio to Participate in the H.C. Wainwright Global Life Sciences Conference

89bio to Participate in the H.C. Wainwright Global Life Sciences Conference Content Import Wed, 03/03/2021 - 08:01 89bio to Participate in the H.C. Wainwright Global Life Sciences Conference 03/03/2021 This release is a backfill from a News Wire …

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference Content Import Wed, 02/24/2021 - 08:00 89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference 02/24/2021 This release is a backfill from a News …
Show more

89bio Frequently Asked Questions

  • When was 89bio founded?

    89bio was founded in 2018.

  • Who are 89bio key executives?

    89bio's key executives are Rohan Palekar, Hank Mansbach and Ryan Martins.

  • How many employees does 89bio have?

    89bio has 19 employees.

  • Who are 89bio competitors?

    Competitors of 89bio include Strides Pharma, Zentiva and Cadila Pharmaceuticals.

  • Where is 89bio headquarters?

    89bio headquarters is located at 142 Sansome St 2nd floor, San Francisco, San Francisco.

  • Where are 89bio offices?

    89bio has offices in San Francisco and Herzliya.

  • How many offices does 89bio have?

    89bio has 2 offices.